582 related articles for article (PubMed ID: 26921100)
21. Immunotherapy approaches to treat adult acute lymphoblastic leukemia.
Maino E; Bonifacio M; Scattolin AM; Bassan R
Expert Rev Hematol; 2016 Jun; 9(6):563-77. PubMed ID: 27011303
[TBL] [Abstract][Full Text] [Related]
22. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia.
Litzow MR
Am Soc Clin Oncol Educ Book; 2013; ():294-9. PubMed ID: 23714527
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia.
Hoelzer D
Curr Opin Oncol; 2013 Nov; 25(6):701-6. PubMed ID: 24097105
[TBL] [Abstract][Full Text] [Related]
24. The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia.
DeAngelo DJ
Hematology Am Soc Hematol Educ Program; 2015; 2015():400-5. PubMed ID: 26637749
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in the treatment of acute lymphoblastic leukemia.
Rafei H; Kantarjian HM; Jabbour EJ
Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
[TBL] [Abstract][Full Text] [Related]
26. A Novel bispecific T-cell engager (BiTE) targeting CD22 and CD3 has both in vitro and in vivo activity and synergizes with blinatumomab in an acute lymphoblastic leukemia (ALL) tumor model.
Meckler JF; Levis DJ; Vang DP; Tuscano JM
Cancer Immunol Immunother; 2023 Sep; 72(9):2939-2948. PubMed ID: 37247022
[TBL] [Abstract][Full Text] [Related]
27. Treatment of relapsed/refractory acute lymphoblastic leukemia.
Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibodies in acute lymphoblastic leukemia.
Jabbour E; O'Brien S; Ravandi F; Kantarjian H
Blood; 2015 Jun; 125(26):4010-6. PubMed ID: 25999456
[TBL] [Abstract][Full Text] [Related]
29. New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia.
Lanza F; Maffini E; Saraceni F; Massari E; Rondoni M; Daghia G; Olivieri A; Cerchione C; Martinelli G
Minerva Med; 2020 Oct; 111(5):478-490. PubMed ID: 32955830
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
31. Current status of antibody therapy in ALL.
Ai J; Advani A
Br J Haematol; 2015 Feb; 168(4):471-80. PubMed ID: 25382151
[TBL] [Abstract][Full Text] [Related]
32. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
33. Novel antibody-based therapies for acute lymphoblastic leukemia.
Hoelzer D
Hematology Am Soc Hematol Educ Program; 2011; 2011():243-9. PubMed ID: 22160041
[TBL] [Abstract][Full Text] [Related]
34. Chemoimmunotherapy in acute lymphoblastic leukemia.
Hoelzer D; Gökbuget N
Blood Rev; 2012 Jan; 26(1):25-32. PubMed ID: 21958552
[TBL] [Abstract][Full Text] [Related]
35. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.
Le Jeune C; Thomas X
Eur J Haematol; 2015 Feb; 94(2):99-108. PubMed ID: 24981395
[TBL] [Abstract][Full Text] [Related]
36. Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia.
Viardot A; Sala E
Expert Opin Investig Drugs; 2021 Jul; 30(7):773-784. PubMed ID: 33998346
[TBL] [Abstract][Full Text] [Related]
37. Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.
Buie LW; Pecoraro JJ; Horvat TZ; Daley RJ
Ann Pharmacother; 2015 Sep; 49(9):1057-67. PubMed ID: 26041811
[TBL] [Abstract][Full Text] [Related]
38. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.
Kantarjian H; Jabbour E
Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308
[TBL] [Abstract][Full Text] [Related]
39. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
40. Antibody therapy for acute lymphoblastic leukemia.
Portell CA; Advani AS
Curr Hematol Malig Rep; 2012 Jun; 7(2):153-9. PubMed ID: 22422550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
